Efficacy of Pazopanib in patients with metastatic uterine sarcoma: A multi-institutional study


Sunar V., Korkmaz V., AKIN S., Guven D. C., ARIK Z., Ates O., ...Daha Fazla

JOURNAL OF BUON, cilt.24, sa.6, ss.2327-2332, 2019 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 24 Sayı: 6
  • Basım Tarihi: 2019
  • Dergi Adı: JOURNAL OF BUON
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.2327-2332
  • Anahtar Kelimeler: pazopanib, sarcoma, uterus, uterine sarcoma, SOFT-TISSUE SARCOMA, PHASE-II TRIAL, EUROPEAN ORGANIZATION, LEIOMYOSARCOMA, GEMCITABINE, DOXORUBICIN, UTERUS, DOCETAXEL, BONE, CHEMOTHERAPY
  • Gazi Üniversitesi Adresli: Evet

Özet

Purpose: Uterine sarcoma accounts for 3-9% of uterine malignant tumors and has poor prognosis. Pazopanib is an oral multi-kinase inhibitor and the only tyrosine kinase inhibitor which has been approved for metastatic soft tissue sarcoma. In the present study we aimed to evaluate the efficacy of pazopanib in metastatic uterine sarcoma.